| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Comparative Fasting Bioavailability of Dispersible and Conventional Tablets of Risperidone: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Male Chinese Volunteers
DOI: 10.1016/j.clinthera.2012.04.027
Background: Risperidone (RIS), an atypical antipsychotic drug, is used for the treatment of psychoses associated with schizophrenia and other psychiatric disorders in adult and pediatric populations. ...
|
Mingzhu Huang,
Jianzhong Shen-Tu,
Xingjiang Hu,
Junchun Chen,
Jian Liu,
Lihua Wu
et al.
|
Full-length article
(In Press Corrected Proof)
|
17 May 2012 |
|
Utilization and Cost in Clinical Practice of Darbepoetin Alfa and Epoetin Alfa
for Anemia Concomitant With Chemotherapy
DOI: 10.1016/j.clinthera.2012.04.020
Background: In 2005, the mean weekly dose ratio of epoetin alfa (EA) to darbepoetin alfa (DA) in clinical practice was estimated to be ∼400 to 1. In 2006, a 500-μg dose and new dosing schedule was app...
|
Ariel Berger,
Claudia Lord,
Patricia K. Corey-Lisle,
G. Rhys Williams,
Gerry Oster
et al.
|
Full-length article
(In Press Corrected Proof)
|
17 May 2012 |
|
Update on Potential Drugs for the Treatment of Diabetic Kidney Disease
DOI: 10.1016/j.clinthera.2012.04.026
Background: Although controlling hyperglycemia and proteinuria is currently the main focus of diabetic kidney disease management, some existing drugs and other new compounds are being evaluated for th...
|
Brian Shepler,
Christy Nash,
Cory Smith,
Abbey DiMarco,
Josie Petty,
Stephanie Szewciw
et al.
|
Review article
(In Press Corrected Proof)
|
14 May 2012 |
|
Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting
DOI: 10.1016/j.clinthera.2012.04.006
Objective: This study assessed the cost-effectiveness of escitalopram for the treatment of depression in the Netherlands from a societal perspective. Methods: A decision tree model was constructed usi...
|
Mark J.C. Nuijten,
Mélanie Brignone,
Florence Marteau,
Johan A.den Boer,
Erik Hoencamp
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer
DOI: 10.1016/j.clinthera.2012.04.008
Background: Denosumab has been approved in the United States for the prevention of skeletal-related events (SREs) in metastatic breast cancer. In a Phase III trial in patients with bone-metastatic bre...
|
Sonya J. Snedecor,
John A. Carter,
Satyin Kaura,
Marc F. Botteman
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
A New Model of Prescription to Nonprescription Reclassification: The Calcipotriol Case Study
DOI: 10.1016/j.clinthera.2012.04.019
Background: Medicines reclassification from prescription to nonprescription (switch) has slowed in some countries, including the United States. New thinking may be necessary to drive this area, includ...
|
Natalie Gauld,
Lynne Emmerton,
Fiona Kelly,
Stephen Buetow
|
Short communication
(In Press Corrected Proof)
|
14 May 2012 |
|
Efficacy and Safety Profile Evaluation of Acarbose Alone and in Association With Other Antidiabetic Drugs: A Systematic Review
DOI: 10.1016/j.clinthera.2012.04.012
Background: Epidemiologic studies have revealed that postprandial hyperglycemia significantly contributes to high glycated hemoglobin concentrations and could be linked to the development of chronic d...
|
Giuseppe Derosa,
Pamela Maffioli
|
Review article
(In Press Corrected Proof)
|
07 May 2012 |
|
Cost-Effectiveness Model of Use of Genetic Testing as an Aid in Assessing the Likely Benefit of Aspirin Therapy for Primary Prevention of Cardiovascular Disease
DOI: 10.1016/j.clinthera.2012.04.004
Background: Aspirin use for the primary prevention of cardiovascular disease (CVD) is controversial because of the need to balance the risk of major bleeding events caused by aspirin with the benefit ...
|
Dov Shiffman,
Katherine Slawsky,
Lauren Fusfeld,
James J. Devlin,
Thomas F. Goss
et al.
|
Full-length article
(In Press Corrected Proof)
|
07 May 2012 |
|
Restrictive Drug Coverage Policies can Induce Substantial Drug Exposure Misclassification in Pharmacoepidemiologic Studies
DOI: 10.1016/j.clinthera.2012.04.009
Background: Drugs reimbursed through a single-party payer such as health maintenance organizations or provincial governments are generally captured in administrative data if they have full-benefit sta...
|
John-Michael Gamble,
Finlay A. McAlister,
Jeffrey A. Johnson,
Dean T. Eurich
|
Full-length article
(In Press Corrected Proof)
|
03 May 2012 |
|
Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes
DOI: 10.1016/j.clinthera.2012.04.005
Background: The clinical benefits of dual antiplatelet treatment (aspirin + clopidogrel) in the management of acute coronary syndromes (ACS) are well established. However, clopidogrel is a prodrug tha...
|
Judy W.M. Cheng
|
Review article
(In Press Corrected Proof)
|
23 April 2012 |
